Literature DB >> 19016696

Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2.

S-J Chen1, T Nakahara, M Takahara, M Kido, L Dugu, H Uchi, S Takeuchi, Y-T Tu, Y Moroi, M Furue.   

Abstract

BACKGROUND: The enzyme mammalian target of rapamycin (mTOR) integrates many different cellular signals to control cell growth and proliferation, protein synthesis and breakdown, and other processes. Dysregulation of mTOR is implicated in a range of human diseases, including cancers and cardiovascular disorders. To date, there has been no report on the expression of protein kinase B (AKT)/mTOR cell signalling in epidermal tumours.
OBJECTIVES: This study was designed to investigate the activation of the mTOR signalling pathway in epidermal tumours and to correlate this with cyclin-dependent kinase 2 (CDK2) expression.
METHODS: Immunohistological staining was performed with phosphorylated (p-) AKT, p-mTOR, p-4E-binding protein 1 (p-4EBP1), p-ribosomal protein S6 (p-S6), p-p70 ribosomal protein S6 kinase 1 (p-p70S6K1) and CDK2 in 15 cases each of seborrhoeic keratosis, actinic keratosis, keratoacanthoma and Bowen's disease (BD), and 25 cases of squamous cell carcinoma (SCC). Fifteen normal skin (NS) samples served as control.
RESULTS: Among 85 tumours, 40 (47%) were positive for p-AKT, 31 (36%) for p-mTOR, 44 (52%) for p-4EBP1, 38 (45%) for p-S6, and 39 (46%) for p-p70S6K1. CDK2 immunostaining was positive in all cases of SCC and BD, and in 67% of benign tumours. All of these markers were stained much more frequently in malignant tumours than in benign tumours or NS. p-AKT, p-mTOR, p-4EBP1, p-p70S6K1 and p-S6 each showed high correlation with CDK2.
CONCLUSIONS: Constitutive activation of the AKT/mTOR pathway was frequent in epidermal tumours, especially in malignant tumours. Activation was highly correlated with CDK2 expression, suggesting that the AKT/mTOR pathway may induce the malignant transition through CDK2 in epidermal tumours.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19016696     DOI: 10.1111/j.1365-2133.2008.08903.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  24 in total

1.  Inhibition of mTOR by apigenin in UVB-irradiated keratinocytes: A new implication of skin cancer prevention.

Authors:  Bryan B Bridgeman; Pu Wang; Boping Ye; Jill C Pelling; Olga V Volpert; Xin Tong
Journal:  Cell Signal       Date:  2016-02-12       Impact factor: 4.315

2.  Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.

Authors:  Jean Christopher Chamcheu; Vaqar M Adhami; Stephane Esnault; Mario Sechi; Imtiaz A Siddiqui; Kenneth A Satyshur; Deeba N Syed; Shah-Jahan M Dodwad; Maria-Ines Chaves-Rodriquez; B Jack Longley; Gary S Wood; Hasan Mukhtar
Journal:  Antioxid Redox Signal       Date:  2016-10-04       Impact factor: 8.401

3.  Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin.

Authors:  Yira Bermudez; Steven P Stratton; Clara Curiel-Lewandrowski; James Warneke; Chengcheng Hu; George T Bowden; Sally E Dickinson; Zigang Dong; Ann M Bode; Kathylynn Saboda; Christine A Brooks; Emanuel F Petricoin; Craig A Hurst; David S Alberts; Janine G Einspahr
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-01

4.  Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma.

Authors:  Janine G Einspahr; Valerie Calvert; David S Alberts; Clara Curiel-Lewandrowski; James Warneke; Robert Krouse; Steven P Stratton; Lance Liotta; Caterina Longo; Giovanni Pellacani; Giovanni Pellicani; Anil Prasad; Paul Sagerman; Yira Bermudez; Jianghong Deng; G Timothy Bowden; Emanuel F Petricoin
Journal:  Cancer Prev Res (Phila)       Date:  2012-03

5.  Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration.

Authors:  Vipin Yadav; Mitchell F Denning
Journal:  Mol Carcinog       Date:  2010-12-10       Impact factor: 4.784

6.  Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma.

Authors:  Guoying Miao; Baoguo Liu; Xiaohui Guo; Xike Zhang; Gui-Jing Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

7.  Conditional disruption of rictor demonstrates a direct requirement for mTORC2 in skin tumor development and continued growth of established tumors.

Authors:  Theresa D Carr; Robert P Feehan; Michael N Hall; Markus A Rüegg; Lisa M Shantz
Journal:  Carcinogenesis       Date:  2015-03-04       Impact factor: 4.944

8.  Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway.

Authors:  Sandeep C Chaudhary; Deepali Kurundkar; Craig A Elmets; Levy Kopelovich; Mohammad Athar
Journal:  Photochem Photobiol       Date:  2012-06-01       Impact factor: 3.421

9.  Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival.

Authors:  Theresa D Carr; John DiGiovanni; Christopher J Lynch; Lisa M Shantz
Journal:  Cancer Prev Res (Phila)       Date:  2012-11-05

10.  Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.

Authors:  Sally E Dickinson; Jaroslav Janda; Jane Criswell; Karen Blohm-Mangone; Erik R Olson; Zhonglin Liu; Christy Barber; Emanuel F Petricoin; Valerie S Calvert; Janine Einspahr; Jesse E Dickinson; Steven P Stratton; Clara Curiel-Lewandrowski; Kathylynn Saboda; Chengcheng Hu; Ann M Bode; Zigang Dong; David S Alberts; G Timothy Bowden
Journal:  Cancer Prev Res (Phila)       Date:  2016-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.